个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Patients with ALK IHC-Positive/FISH-Negative NSCLC Benefit from ALK TKI Treatment: Response Data from the Global ALEX Trial

| 认领 | 导出 | |

文献详情

资源类型：
作者：
Mok, T.[1] * ; Peters, S.[2] ; Camidge, D. Ross[3] ; Gadgeel, S.[4] ; Ou, S. I.[5] ; Kim, D.[6] ; Dziadziuszko, R.[7] ; De Marinis, F.[8] ; Sangha, R.[9,10] ; Zeaiter, A.[11] ; Noe, J.[11] ; Nueesch, E.[11] ; Liu, T.[11] ; Loftin, I.[12] ; Williams, C.[12] ; Shaw, A.[13] ;
机构： [1]Chinese Univ Hong Kong, Hong Kong Canc Inst, State Key Lab South China, Shatin, Hong Kong, Peoples R China [2]Lausanne Univ Hosp, Lausanne, Switzerland [3]Univ Colorado, Denver, CO 80202 USA [4]Wayne State Univ, Karmanos Canc Inst, Detroit, IL USA [5]Univ Calif Irvine, Sch Med, Chao Family Comprehens Canc Ctr, Orange, CA USA [6]Seoul Natl Univ Hosp, Seoul, South Korea [7]Med Univ Gdansk, Gdansk, Poland [8]Ist Europeo Oncol, Milan, Italy [9]Cross Canc Inst, Edmonton, AB, Canada [10]Univ Alberta, Edmonton, AB, Canada [11]F Hoffmann La Roche Ltd, Basel, Switzerland [12]Ventana Med Syst Inc, Tucson, AZ USA [13]Massachusetts Gen Hosp, Boston, MA 02114 USA
出处：
DOI： 10.1016/j.jtho.2017.09.314
ISSN：

关键词： Alectinib NSCLC FISH

语种：
外文
被引次数：
WOS：
中科院(CAS)分区：
出版当年[2017]版：
大类 | 2 区 医学
小类 | 2 区 肿瘤学 2 区 呼吸系统
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
第一作者：
第一作者机构： [1]Chinese Univ Hong Kong, Hong Kong Canc Inst, State Key Lab South China, Shatin, Hong Kong, Peoples R China
推荐引用方式(GB/T 7714)：
Mok T.,Peters S.,Camidge D. Ross,et al.Patients with ALK IHC-Positive/FISH-Negative NSCLC Benefit from ALK TKI Treatment: Response Data from the Global ALEX Trial[J].JOURNAL OF THORACIC ONCOLOGY.2017,12(11):S1739-S1740.doi:10.1016/j.jtho.2017.09.314.
APA：
Mok, T.,Peters, S.,Camidge, D. Ross,Gadgeel, S.,Ou, S. I....&Shaw, A..(2017).Patients with ALK IHC-Positive/FISH-Negative NSCLC Benefit from ALK TKI Treatment: Response Data from the Global ALEX Trial.JOURNAL OF THORACIC ONCOLOGY,12,(11)
MLA：
Mok, T.,et al."Patients with ALK IHC-Positive/FISH-Negative NSCLC Benefit from ALK TKI Treatment: Response Data from the Global ALEX Trial".JOURNAL OF THORACIC ONCOLOGY 12..11(2017):S1739-S1740

相关文献

[1]A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report [2]Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC : Five-Year Update From the Phase 3 ALESIA Study [3]A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report [4]NGS and FISH for MET amplification detection in EGFR TKI resistant non-small cell lung cancer (NSCLC) patients: A prospective, multicenter study in China [5]Alectinib (ALC) vs crizotinib (CRZ) in treatment-naive ALK plus non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study [6]Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC [7]Comparison of HER2 and Lauren Classification between Biopsy and Surgical Resection Samples, Primary and Metastatic Samples of Gastric Cancer [8]中、晚期非小细胞肺癌144例用CAP、EP、IP三方案化疗疗效、毒性比较 [9]Unfavorable Prognostic Impact of HER2 2+/FISH-Negativity in Older Patients with HER2-Negative and High-Risk Breast Cancer [10]Alectinib ( CH5424802) antagonizes ABCB1-and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo

资源点击量：52808 今日访问量：2 总访问量：4561 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号